Eli Lilly acquisition of Verve signals renewed interest in gene editing — Jun 18th, 2025

Eli Lilly (NYSE:LLY), a prominent player in the pharmaceuticals industry with a market capitalization of $710 billion, has reached an agreement to acquire Verve Therapeutics (NASDAQ:VERV), marking what Citizens JMP analysts call "an important milestone" for gene-editing technology. The d...

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities — Jun 17th, 2025

PALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report, Grand View Research said that the gl...

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 — Jun 20th, 2025

Novo Nordisk A/S Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions.1,2 Oral amycretin phase 1 data on t...

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick — Jun 20th, 2025

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...

GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? — Jun 18th, 2025

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the...

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities — Jun 17th, 2025

PALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report,  Grand View Research said that the g...

NVO Factor-Based Stock Analysis - Warren Buffett — Jun 18th, 2025

Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability a...

European shares fall as Middle East tensions weigh; eyes on Fed decision — Jun 18th, 2025

By Purvi Agarwal, Sanchayaita Roy and Ragini Mathur (Reuters) -European shares declined on Wednesday as investors awaited the Federal Reserve’s monetary policy decision, with ongoing tensions in the Middle East adding to market uncertainty. The pan-European STOXX 600 index closed 0.4% ...

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says — Jun 20th, 2025

By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen co...

Global pharma stocks down as Trump renews tariff threat — Jun 17th, 2025

Chip Somodevilla/Getty Images News Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his plans to impose tariffs on pharmaceutical goods, a product category that has largely been immune from trade war due to public healt...

LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? — Jun 20th, 2025

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, strong market capitalization and global footprint. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also ...

Market Voices: July Fed rate cut eyed, GLP-1s, Darden, Aflac, JPMorgan — Jun 20th, 2025

[Indianapolis - April 2016: Eli Lilly and Company V] jetcityimage _Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. _ * Federal Reserve Governor Christopher Waller said Friday that the Fed could implement an interest rate c...

Novo Nordisk focused on biotech deals for cardiometabolic indications — Jun 17th, 2025

[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer In the aftermath of several deals with smaller biotechs made in the 13 months in t...

Ricks Is the King of Pharma, Thanks to Lilly’s Zepbound — Jun 20th, 2025

Under CEO Dave Ricks, 58, Eli Lilly seems to have won the weight-loss war. Lilly’s Danish rival, Novo Nordisk had the early advantage, launching its obesity drug Wegovy two years before the Food and Drug Administration approved Lilly’s Zepbound. Enthusiasm for the stocks was boundless:...

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand — Jun 20th, 2025

By Rishika Sadam (Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to intro...

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet — Jun 20th, 2025

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2 PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Nov...

Warren Buffett Detailed Fundamental Analysis - NVO — Jun 20th, 2025

Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability a...

American College of Cardiology urges wider use of weight-loss drugs — Jun 20th, 2025

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more Americans should be taking weight-loss drugs to prevent heart disease. The nation’s top cardiology organization now advises that medications like Novo Nordisk (NYSE:NVO)...

Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal — Jun 18th, 2025

Eli Lilly and Company (NYSE:LLY), a prominent pharmaceutical player with a market capitalization of $710 billion and impressive revenue growth of 36% over the last twelve months, is acquiring Verve Therapeutics for $1.3 billion. Bernstein SocGen Group has responded by reiterating its Outpe...

Scholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drug — Jun 18th, 2025

[Two injectors dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication hovering over a blue background. Yellow measuring tape around the injectors.] Alones Creative Scholar Rock (NASDAQ:SRRK [https://seekingalpha.com/symbol/SRRK]) announced Wednesday t...

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand — Jun 20th, 2025

By Rishika Sadam (Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world’s most populous country. The U.S.-based Lilly beat rival Novo Nordisk (NYSE:NVO) in March this ...

Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do? — Jun 16th, 2025

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge fund, Parvus Asset Management, building a stake in the company, as well as a positive pipeline update from the development program of one of NVO’s next-generation...

Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? — Jun 18th, 2025

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglutide, a GLP-1 receptor agonist. While Ozempic was first approved in 2017, Wego...

Notable healthcare headlines for the week: Novo Nordisk, Thermo Fisher and UnitedHealth in focus — Jun 15th, 2025

Wall Street's major averages plummeted on Friday after Israel and Iran traded missile strikes and stoked concerns of an all-out war in the Middle East. Iran retaliated on Friday with its own projectiles after Israel’s attack on some of Iran’s nuclear sites and military targets on late...

White House reportedly eyeing restrictions to prescription drug advertising — Jun 17th, 2025

[The White House in Washington DC] lucky-photographer The U.S. government is looking for ways to restrict the pharma sector’s direct-to-consumer advertising to make it more difficult and costly for companies to run advertisements directly targeting patients, Bloomberg News reported Tues...

Nvidia (NVDA) Teams With Novo Nordisk to Advance AI Drug Discovery — Jun 16th, 2025

Nvidia (NVDA, Financials) said Tuesday it is partnering with Novo Nordisk to accelerate drug discovery using its generative and agentic AI tools. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The collaboration will use Denmark's sovereign AI supercomputer, Gefion, operated b...

Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event — Jun 20th, 2025

[GLP-1 related drugs newspaper headlines with hand and magnifying glass] Leading weight loss drug developers Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]), Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]), and Amgen (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN])...

Bariatric surgery better than GLP-1 drugs for weight loss : ASMBS study — Jun 18th, 2025

[Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design] aprott/iStock via Getty Images A study presented at the American Society for Metabolic...

Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now — Jun 18th, 2025

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow can come from bond...

Novo Nordisk Reclaims Top Spot in Europe by Market Value — Jun 17th, 2025

Novo Nordisk A/S (NYSE:NVO) is among the best bear market stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) has reclaimed its crown as Europe’s most valuable publicly traded company, surpassing German software giant SAP SE (ETR:SAPG). With a market capitalization of $355.9...

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? — Jun 19th, 2025

Earlier this week, Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion. The acquisition will add Verve’s pipeline of gene therapies targeting heart diseases, including VERVE-102, an investigational in vivo gene-edit...

How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl — Jun 19th, 2025

In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market. Continue Reading View Comments...

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee — Jun 17th, 2025

The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not paying a nominal maintenance fee years before it became a blockbuster drug for fighting diabetes and obesity, Science reported. Novo Nordisk generates billions of dolla...

Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs — Jun 17th, 2025

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ rather than negative. Continue Reading...

Eli Lilly acquisition of Verve signals renewed interest in gene editing — Jun 18th, 2025

Eli Lilly (NYSE:LLY), a prominent player in the pharmaceuticals industry with a market capitalization of $710 billion, has reached an agreement to acquire Verve Therapeutics (NASDAQ:VERV), marking what Citizens JMP analysts call "an important milestone" for gene-editing technology. The d...

US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list — Jun 18th, 2025

By Diana Novak Jones -A federal judge in Texas has upheld the U.S. Food and Drug Administration’s decision to remove Novo Nordisk (NYSE:NVO)’s blockbuster drugs Ozempic and Wegovy from the shortage list, rejecting a challenge brought by compounding pharmacies who sought to continue ma...

FDA's Makary talks up modernizing agency to get drugs to market faster — Jun 17th, 2025

[Martin Makary Testifies In Nomination Hearing To Be Commissioner Of Food And Drugs At HHS Department] Kayla Bartkowski/Getty Images News FDA Commissioner Marty Makary said that one of his key priorities is to modernize the agency by streamlining the drug review process, using AI tools mo...

LifeMD Announces Annual Meeting Results — Jun 16th, 2025

LifeMD , Inc. (NASDAQ:LFMD), a provider of telehealth services and products with a market capitalization of $613 million, conducted its annual meeting of stockholders on June 13, 2025, where it successfully passed all proposed resolutions. The meeting saw the re-election of seven directors...

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand — Jun 20th, 2025

By Rishika Sadam (Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world’s most populous country. The U.S.-based Lilly beat rival Novo Nordisk (NYSE:NVO) in March this ...

Eli Lilly's SWOT analysis: stock poised for growth amid challenges in GLP-1 market — Jun 18th, 2025

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical giant, has been making waves in the healthcare sector with its innovative treatments for diabetes, obesity, and other therapeutic areas. With an impressive "GREAT" financial health score according to InvestingPro analysis and a robu...

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says — Jun 20th, 2025

By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to ...

Weight-loss drugs should be among primary options to prevent heart disease: cardiology experts — Jun 20th, 2025

[Ozempic Insulin injection pen] CR/iStock via Getty Images Shares of weight-loss drugmakers Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) and Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) spiked after the American College of Cardiology (ACC) recommended that obesit...

Skye confirms phase 2 data on nimacimab for obesity expected later this year — Jun 19th, 2025

[Obesity card in hands of Medical Doctor] Michail_Petrov-96/iStock via Getty Images Phase 2a data on Skye Bioscience's (NASDAQ:SKYE [https://seekingalpha.com/symbol/SKYE]) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be released in late Q3 or early Q4, the company's...

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand — Jun 20th, 2025

By Rishika Sadam (Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to intro...

Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? — Jun 18th, 2025

Key Points Novo Nordisk has been actively pursuing licensing deals over the past six months. These have helped the company improve its pipeline in its most important area. There are other good reasons to consider investing in Novo Nordisk right now. 10 stocks we like better than Novo Nord...

Trump's big beautiful bill: What the pharma industry is watching — Jun 17th, 2025

Pharmaceutical stocks, including Pfizer (PFE), Johnson & Johnson (JNJ), Abbvie (ABBV), Novo Nordisk (NVO), and Astrazeneca (AZN), are falling after President Trump said tariffs on the industry are coming "very soon." Chris Meekins, managing director and Washington health policy research a...

Novo Nordisk stock rating reiterated at Buy by TD Cowen — Jun 18th, 2025

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE:NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with a market capitalization of $331 billion, currently trades at $74.39, with analyst targets...

Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock — Jun 18th, 2025

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing m...

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA — Jun 20th, 2025

Novo Nordisk A/S Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 2...

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It — Jun 18th, 2025

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned +9%, compared to the Zacks S&P...